Grail's Multi-Cancer Early Detection Test Faces Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Trial Results Disappointment: Grail's Galleri test failed to meet its primary endpoint in the NHS trial, showing no statistically significant reduction in Stage III-IV cancer detection, which has led to a more than 30% decline in stock price in 2026, reflecting market concerns about its future prospects.
- Follow-Up Data Potential: Management anticipates that the 12-month follow-up data from the NHS trial will reveal more undetected cancers, thereby supporting the efficacy of the Galleri test in early cancer detection, which could influence insurance coverage decisions positively.
- Deadly Cancer Detection Trend: Management highlighted a favorable trend in detecting 12 deadly cancers in the NHS trial, with sensitivity significantly higher than for other cancers, which may prompt insurers to reassess the cost-benefit analysis of the Galleri test.
- Positive Predictive Value Advantage: The Galleri test demonstrated positive predictive values of 52% and 60.3% in the NHS and PATHFINDER trials, respectively, indicating its effectiveness in cancer detection, which could attract insurers' attention to its relative cost-effectiveness and drive broader adoption.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 59.450
Low
38.00
Averages
60.86
High
83.71
Current: 59.450
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail's Multi-Cancer Early Detection Test Faces Challenges
- Trial Results Disappointment: Grail's Galleri test failed to meet its primary endpoint in the NHS trial, showing no statistically significant reduction in Stage III-IV cancer detection, which has led to a more than 30% decline in stock price in 2026, reflecting market concerns about its future prospects.
- Follow-Up Data Potential: Management anticipates that the 12-month follow-up data from the NHS trial will reveal more undetected cancers, thereby supporting the efficacy of the Galleri test in early cancer detection, which could influence insurance coverage decisions positively.
- Deadly Cancer Detection Trend: Management highlighted a favorable trend in detecting 12 deadly cancers in the NHS trial, with sensitivity significantly higher than for other cancers, which may prompt insurers to reassess the cost-benefit analysis of the Galleri test.
- Positive Predictive Value Advantage: The Galleri test demonstrated positive predictive values of 52% and 60.3% in the NHS and PATHFINDER trials, respectively, indicating its effectiveness in cancer detection, which could attract insurers' attention to its relative cost-effectiveness and drive broader adoption.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc. regarding misleading statements about the NHS-Galleri trial's failure to achieve a statistically significant reduction in Stage III and IV cancers, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs in the class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the primary endpoint was not observed in the NHS-Galleri trial, the stock price plummeted from $101.53 to $50.21 per share, representing a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- Insufficient Disclosure: Grail provided overly optimistic statements about the trial's design being sufficient to demonstrate the primary endpoint's achievability while concealing that the trial period and screening duration were likely inadequate, misleading investors about the trial's true status.
- Investor Rights Protection: Faruqi & Faruqi encourages investors who purchased Grail stock between May 13, 2025, and February 19, 2026, to contact them to discuss their legal rights and seek compensation, ensuring that investors can assert their rights in the class action lawsuit.
See More
Notice of Class Action Lawsuit for GRAIL, Inc. Shareholders
- Lawsuit Background: GRAIL, Inc. faces a class action lawsuit for allegedly providing misleading positive statements to investors during the class period from May 13, 2025, to February 19, 2026, encouraging shareholders to contact Gross Law Firm for potential lead plaintiff appointment.
- Trial Results Disclosure: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, leading to a dramatic stock price drop of approximately 50.55% in one day, from $101.53 to $50.21 per share, reflecting extreme market pessimism about the company's future.
- Allegations of Concealment: The lawsuit claims that GRAIL failed to provide detailed topline results during the trial, potentially concealing trends indicating a longer timeline was necessary to achieve statistical significance, exacerbating investor losses.
- Shareholder Action Recommendation: Shareholders are advised to register for the class action by August 4, 2026, to receive portfolio monitoring services and ensure their rights are protected throughout the case lifecycle.
See More
GRAIL Inc. Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. and its executives for securities fraud related to the NHS-Galleri cancer trial, indicating a severe breach of investor trust following a significant stock drop.
- Stock Price Plunge: On February 20, 2026, GRAIL's stock plummeted 50.55% from $101.53 to $50.21 per share, reflecting a drastic loss in investor value and signaling a pessimistic outlook on the company's future prospects.
- Trial Results Disappointment: Despite GRAIL's previous assertions of favorable outcomes from the NHS-Galleri trial, the failure to meet the primary endpoint of reducing late-stage cancer rates has exacerbated investor disappointment and raised concerns about the company's credibility.
- Legal Implications: Investors have until August 4, 2026, to apply for lead plaintiff status, and a successful lawsuit could significantly impact GRAIL's financial health and future fundraising efforts, further challenging the company's market reputation.
See More
Class Action Notice for GRAIL, Inc. Investors
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for investors who purchased common stock between May 13, 2025, and February 19, 2026, indicating significant legal risks that could impact stock performance.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, suggesting a risk-free legal avenue for affected shareholders, which may encourage broader participation.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its influence and expertise in the industry, potentially boosting investor confidence in the lawsuit.
- Case Details Disclosure: The lawsuit alleges that GRAIL provided misleading information regarding its NHS-Galleri trial and failed to disclose critical data, resulting in investor losses, highlighting significant deficiencies in the company's transparency and information disclosure that could affect its future market reputation.
See More
Reminder of Shareholder Class Action Lawsuits and Deadlines
- Grail Lawsuit Overview: The class action lawsuit against Grail, Inc. alleges that the company made materially false or misleading statements between May 13, 2025, and February 19, 2026, impacting investor decisions; affected shareholders can apply to be lead plaintiffs by August 4, 2026, if they suffered losses during this period.
- Verra Lawsuit Details: The class action against Verra Mobility Corporation claims that the company failed to disclose its revenue outlook for the Commercial Services segment between February 24, 2026, and May 26, 2026, leading to investor losses, with a deadline of August 4, 2026, for lead plaintiff applications.
- BitGo Lawsuit Information: The class action lawsuit against BitGo Holdings, Inc. alleges that the company did not adequately disclose the risks posed by falling digital asset prices to its financial performance; investors who purchased shares during the relevant period and suffered losses can apply to be lead plaintiffs by August 7, 2026.
- Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has been representing shareholders since 2000, recovering hundreds of millions of dollars for victims of corporate misconduct, emphasizing its commitment to vigorous legal representation.
See More
Grail's Multi-Cancer Early Detection Test Faces Challenges
- Trial Results Disappointment: Grail's Galleri test failed to meet its primary endpoint in the NHS trial, showing no statistically significant reduction in Stage III-IV cancer detection, which has led to a more than 30% decline in stock price in 2026, reflecting market concerns about its future prospects.
- Follow-Up Data Potential: Management anticipates that the 12-month follow-up data from the NHS trial will reveal more undetected cancers, thereby supporting the efficacy of the Galleri test in early cancer detection, which could influence insurance coverage decisions positively.
- Deadly Cancer Detection Trend: Management highlighted a favorable trend in detecting 12 deadly cancers in the NHS trial, with sensitivity significantly higher than for other cancers, which may prompt insurers to reassess the cost-benefit analysis of the Galleri test.
- Positive Predictive Value Advantage: The Galleri test demonstrated positive predictive values of 52% and 60.3% in the NHS and PATHFINDER trials, respectively, indicating its effectiveness in cancer detection, which could attract insurers' attention to its relative cost-effectiveness and drive broader adoption.
See More
Investigation Launched into Grail Securities Litigation
- Investigation Initiated: Faruqi & Faruqi, LLP is investigating potential claims against Grail, Inc. regarding misleading statements about the NHS-Galleri trial's failure to achieve a statistically significant reduction in Stage III and IV cancers, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs in the class action.
- Stock Price Plunge: Following Grail's announcement on February 19, 2026, that the primary endpoint was not observed in the NHS-Galleri trial, the stock price plummeted from $101.53 to $50.21 per share, representing a dramatic decline of approximately 50.55% in just one day, resulting in significant losses for investors.
- Insufficient Disclosure: Grail provided overly optimistic statements about the trial's design being sufficient to demonstrate the primary endpoint's achievability while concealing that the trial period and screening duration were likely inadequate, misleading investors about the trial's true status.
- Investor Rights Protection: Faruqi & Faruqi encourages investors who purchased Grail stock between May 13, 2025, and February 19, 2026, to contact them to discuss their legal rights and seek compensation, ensuring that investors can assert their rights in the class action lawsuit.
See More
Notice of Class Action Lawsuit for GRAIL, Inc. Shareholders
- Lawsuit Background: GRAIL, Inc. faces a class action lawsuit for allegedly providing misleading positive statements to investors during the class period from May 13, 2025, to February 19, 2026, encouraging shareholders to contact Gross Law Firm for potential lead plaintiff appointment.
- Trial Results Disclosure: On February 19, 2026, GRAIL announced that the NHS-Galleri trial did not observe a statistically significant reduction in Stage III-IV cancers, leading to a dramatic stock price drop of approximately 50.55% in one day, from $101.53 to $50.21 per share, reflecting extreme market pessimism about the company's future.
- Allegations of Concealment: The lawsuit claims that GRAIL failed to provide detailed topline results during the trial, potentially concealing trends indicating a longer timeline was necessary to achieve statistical significance, exacerbating investor losses.
- Shareholder Action Recommendation: Shareholders are advised to register for the class action by August 4, 2026, to receive portfolio monitoring services and ensure their rights are protected throughout the case lifecycle.
See More
GRAIL Inc. Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Leading securities law firm Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. and its executives for securities fraud related to the NHS-Galleri cancer trial, indicating a severe breach of investor trust following a significant stock drop.
- Stock Price Plunge: On February 20, 2026, GRAIL's stock plummeted 50.55% from $101.53 to $50.21 per share, reflecting a drastic loss in investor value and signaling a pessimistic outlook on the company's future prospects.
- Trial Results Disappointment: Despite GRAIL's previous assertions of favorable outcomes from the NHS-Galleri trial, the failure to meet the primary endpoint of reducing late-stage cancer rates has exacerbated investor disappointment and raised concerns about the company's credibility.
- Legal Implications: Investors have until August 4, 2026, to apply for lead plaintiff status, and a successful lawsuit could significantly impact GRAIL's financial health and future fundraising efforts, further challenging the company's market reputation.
See More
Class Action Notice for GRAIL, Inc. Investors
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for investors who purchased common stock between May 13, 2025, and February 19, 2026, indicating significant legal risks that could impact stock performance.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, suggesting a risk-free legal avenue for affected shareholders, which may encourage broader participation.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its influence and expertise in the industry, potentially boosting investor confidence in the lawsuit.
- Case Details Disclosure: The lawsuit alleges that GRAIL provided misleading information regarding its NHS-Galleri trial and failed to disclose critical data, resulting in investor losses, highlighting significant deficiencies in the company's transparency and information disclosure that could affect its future market reputation.
See More
Reminder of Shareholder Class Action Lawsuits and Deadlines
- Grail Lawsuit Overview: The class action lawsuit against Grail, Inc. alleges that the company made materially false or misleading statements between May 13, 2025, and February 19, 2026, impacting investor decisions; affected shareholders can apply to be lead plaintiffs by August 4, 2026, if they suffered losses during this period.
- Verra Lawsuit Details: The class action against Verra Mobility Corporation claims that the company failed to disclose its revenue outlook for the Commercial Services segment between February 24, 2026, and May 26, 2026, leading to investor losses, with a deadline of August 4, 2026, for lead plaintiff applications.
- BitGo Lawsuit Information: The class action lawsuit against BitGo Holdings, Inc. alleges that the company did not adequately disclose the risks posed by falling digital asset prices to its financial performance; investors who purchased shares during the relevant period and suffered losses can apply to be lead plaintiffs by August 7, 2026.
- Law Firm Background: Holzer & Holzer, LLC is a highly rated securities litigation law firm that has been representing shareholders since 2000, recovering hundreds of millions of dollars for victims of corporate misconduct, emphasizing its commitment to vigorous legal representation.
See More
